Search - tctmd.com

Displaying 701 - 720 of 849

Sort: Relevancy | Date

News Daily News

Focused Update to Valve Guidelines Tackles Intermediate-Risk TAVR, Anticoagulation for A-fib

Todd Neale

March 15, 2017

News Daily News

NOACs Seem to Perform Just Fine in Patients With A-fib and Most Types of Valvular Disease

Todd Neale

March 14, 2017

Presentation SIF 2017

Novel Applications: Utilizing Impella to Support TAVR Patients

Presenter: Robert D. Riley

March 11, 2017

Presentation SIF 2017

Cardiologists "Need" the Surgeons to Optimize the Quality of Their Structural Heart Program

Presenter: Robert D. Riley

March 11, 2017

Presentation SIF 2017

TAVR Durability: Recent Insights

Presenter: David L. Brown

March 11, 2017

Presentation SIF 2017

Bicuspid Valve Disease

Presenter: Michael J. Reardon

March 11, 2017

Presentation SIF 2017

TAVR Will Be Default in Low Risk Patients

Presenter: David L. Brown

March 11, 2017

Presentation SIF 2017

Optimizing Program Efficiency

Presenter: Vinod H. Thourani

March 11, 2017

Presentation SIF 2017

Next Generation TAVR Devices with Case Examples

Presenter: David G. Rizik

March 11, 2017

Presentation SIF 2017

Not So Fast: SAVR Will Win

Presenter: Michael J. Reardon

March 11, 2017

Presentation SIF 2017

Coronary Disease and TAVR

Presenter: Robert J. Applegate

March 11, 2017

Presentation SIF 2017

Best Practices: Evolut R

Presenter: Ramon Quesada

March 11, 2017

Presentation SIF 2017

Valve-in-Valve: What You Need to Know

Presenter: Samir Kapadia

March 11, 2017

Presentation SIF 2017

Best Practices: Sapien 3

Presenter: Samir Kapadia

March 11, 2017

Presentation SIF 2017

Conduction Abnormalities Post TAVR

Presenter: William B. Bachinsky

March 11, 2017

Presentation SIF 2017

Bicuspid Aortic Valve Disease and TAVR

Presenter: Michael J. Reardon

March 11, 2017

Presentation SIF 2017

State of the Art 2017: How You Will Be Managing Aortic Stenosis in 2020?

Presenter: Vinod H. Thourani

March 11, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

Presentation SIF 2017

If at First It Doesn’t Succeed…

Presenter: Molly Szerlip

March 09, 2017

Presentation SIF 2017

Learning From the Experts: A Review of Degenerative, Functional and Mixed Etiology Mitral Regurgitation

Presenter: Robert F. Burke

March 09, 2017

Advertisement

Focused Update to Valve Guidelines Tackles Intermediate-Risk TAVR, Anticoagulation for A-fib

NOACs Seem to Perform Just Fine in Patients With A-fib and Most Types of Valvular Disease

Novel Applications: Utilizing Impella to Support TAVR Patients

Cardiologists "Need" the Surgeons to Optimize the Quality of Their Structural Heart Program

TAVR Durability: Recent Insights

Bicuspid Valve Disease

TAVR Will Be Default in Low Risk Patients

Optimizing Program Efficiency

Next Generation TAVR Devices with Case Examples

Not So Fast: SAVR Will Win

Coronary Disease and TAVR

Best Practices: Evolut R

Valve-in-Valve: What You Need to Know

Best Practices: Sapien 3

Conduction Abnormalities Post TAVR

Bicuspid Aortic Valve Disease and TAVR

State of the Art 2017: How You Will Be Managing Aortic Stenosis in 2020?

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

If at First It Doesn’t Succeed…

Learning From the Experts: A Review of Degenerative, Functional and Mixed Etiology Mitral Regurgitation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content